Journal
BIOMATERIALS
Volume 31, Issue 28, Pages 7355-7363Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2010.05.061
Keywords
Drug nanocarriers; Taxane drug; Paclitaxel; Prostate cancer; Polyaniline derivative
Funding
- National Science Council of the Republic of China
- Chang Gung Molecular Medicine Research Center
- Chang Gung Memorial Hospital
- [NSC 94-2216-E-182-001]
- [NSC 96-2314-B-182A-023-MY2]
- [CMRPD140041]
- [CMRPD250013]
- [CMRPD350353]
- [UERPD270201]
Ask authors/readers for more resources
A nontoxic drug nanocarrier containing carboxyl groups was successfully developed by mixing magnetic nanoparticles (MNPs) of Fe3O4 with the water-soluble polyaniline derivative poly[aniline-co-sodium N-(1-one-butyric acid) aniline] (SPAnNa) and doping with HCl aqueous solution to form SPAnH/MNPs shell/core. SPAnH/MNPs could be used to effectively immobilize the hydrophobic drug paclitaxel (PTX), thus enhancing the drug's thermal stability and water solubility. Up to 302.75 mu g of PTX could be immobilized per mg of SPAnH/MNPs. SPAnH/MNPs-bound-PTX (bound-PTX) was more stable than free-PTX at both 25 degrees C and 37 degrees C. Furthermore, bound-PTX was more cytotoxic to human prostate carcinoma cells (PC3 and CWR22R) than free-PTX at 37 degrees C, and the inhibition of cellular growth was even more pronounced when magnetic targeting was applied to the bound-PTX. These data indicate that this magnetically targeted drug delivery system provides more effective treatment of prostate cancer cells using lower therapeutic doses and thus with potentially fewer side-effects. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available